tbuckley/cabot-search huggingface dataset:
Lamb ingestion and odynophagia
Authors: Raghav C Dwivedi, Bruno Kenway, K Haribaskaran, Piyush Jani
Journal: BMJ (2016)

A 40 year old man presented to his local emergency department a few hours after swallowing a piece of lamb that felt immediately sharp on the left side of his throat. He was unable to finish the meal but was able to swallow saliva. He underwent lateral radiography of soft neck tissue (fig 1⇓) and no food bolus or foreign body was visualised. He was reassured and referred to the local ear, nose, and throat (ENT) department the next day. His odynophagia persisted; no foreign body was evident on flexible nasendoscopy but the left arytenoid region showed mild oedema. The patient was again reassured and discharged by the ENT team. Fifteen days later the patient re-presented to the emergency department with increasing left neck pain on swallowing. He was able to swallow solids and liquids and was systemically well. No foreign body or pooling of saliva was evident on flexible nasendoscopy. Neck examination did not show any subcutaneous emphysema, but a slight fullness and tenderness was noted in the left thyroid region.



Fig 1  Lateral radiograph of soft tissue in neck





### 1. What is the most likely diagnosis?

#### Short answer

Missed ingested foreign body with possible complications.

#### Discussion

Based on the clinical presentation, the possibility of a missed foreign body with complications that are suppurative (deep neck space abscess) or vascular (injury to internal jugular vein/tributaries, carotid artery/branches) should always be considered, especially in patients presenting with persistent, worsening, or evolving symptoms. On close inspection a foreign body can be seen in the lateral radiograph (fig 1⇑). Sharp foreign bodies, such as fish bones, food boluses containing bone, metal, or glass are notorious as they can penetrate the lining of the pharynx or oesophagus and lodge …
Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib
Authors: K Shide, T Kameda, T Yamaji, M Sekine, N Inada, A Kamiunten, K Akizuki, K Nakamura, T Hidaka, Y Kubuki, H Shimoda, A Kitanaka, A Honda, A Sawaguchi, H Abe, T Miike, H Iwakiri, Y Tahara, M Sueta, S Hasuike, S Yamamoto, K Nagata, K Shimoda
Journal: Leukemia (2016)

Mutations of calreticulin (CALR) are detected in 25–30% of patients with essential thrombocythemia (ET) or primary myelofibrosis and cause frameshifts that result in proteins with a novel C-terminal. We demonstrate that CALR mutations activated signal transducer and activator of transcription 5 (STAT5) in 293T cells in the presence of thrombopoietin receptor (MPL). Human megakaryocytic CMK11-5 cells and erythroleukemic F-36P-MPL cells with knocked-in CALR mutations showed increased growth and acquisition of cytokine-independent growth, respectively, accompanied by STAT5 phosphorylation. Transgenic mice expressing a human CALR mutation with a 52 bp deletion (CALRdel52-transgenic mice (TG)) developed ET, with an increase in platelet count, but not hemoglobin level or white blood cell count, in association with an increase in bone marrow (BM) mature megakaryocytes. CALRdel52 BM cells did not drive away wild-type (WT) BM cells in in vivo competitive serial transplantation assays, suggesting that the self-renewal capacity of CALRdel52 hematopoietic stem cells (HSCs) was comparable to that of WT HSCs. Therapy with the Janus kinase (JAK) inhibitor ruxolitinib ameliorated the thrombocytosis in TG mice and attenuated the increase in number of BM megakaryocytes and HSCs. Taken together, our study provides a model showing that the C-terminal of mutant CALR activated JAK-STAT signaling specifically downstream of MPL and may have a central role in CALR-induced myeloproliferative neoplasms.
Reactivation of Cytomegalovirus Following Reduced-Intensity Cord Blood Transplantation for Adult Patients.
Authors: Tomoko Matsumura, Masahiro Kami, Eiji Kusumi, Tomohiro Myojo, Shinsuke Takagi, Daisuke Kato, Koichiro Yuji, Naoyuki Uchida, Kazuhiro Masuoka, Atsushi Wake, Shigesaburo Miyakoshi, Shinichi Morinaga, Yoshinobu Kanda, Shuichi Taniguchi
Journal: Blood (2005)
Anti-Tumor Activity of IPI-504, a Novel Hsp90 Inhibitor in Multiple Myeloma.
Authors: Vito J. Palombella, Emmanuel Normant, Janid Ali, John Barrett, Michael Foley, Yun Gao, Jennie Ge, Asimina T. Georges, David Grayzel, Louis Grenier, Jebecka Hudak, Roger Pak, Jon Patterson, Christine Pien, Melissa Pink, James Porter, Junbiao Sang, Kerry Spear, Jens Sydor, Jim Wright, Constantine S. Mitsiades, Kenneth C. Anderson, Julian Adams, Jeffrey Tong
Journal: Blood (2004)
Percutaneous Nephrolithotomy: Update, Trends, and Future Directions for Simultaneous Supine Percutaneous Nephrolithotomy and Retrograde Ureterolithotripsy in the Galdakao-modified Supine Valdivia Position for Large Proximal Ureteral Calculi
Authors: Tsung-Yi Huang, Kathy Ming Feng, Ing-Shiang Lo
Journal: European Urology (2016)
Comprehensive Computational Pathological Image Analysis Predicts Lung Cancer Prognosis
Authors: Xin Luo, Xiao Zang, Lin Yang, Junzhou Huang, Faming Liang, Jaime Rodriguez-Canales, Ignacio I. Wistuba, Adi Gazdar, Yang Xie, Guanghua Xiao
Journal: Journal of Thoracic Oncology (2016)
De Novo CD5+ Diffuse Large B-Cell Lymphoma: Result of a Detail Morphologic Evaluation and Long-Term Follow Up of 128 Patients.
Authors: Motoko Yamaguchi, Naoya Nakamura, Ritsuro Suzuki, Yoshitoyo Kagami, Masataka Okamoto, Ryo Ichinohasama, Tadashi Yoshino, Junji Suzumiya, Takuhei Murase, Ikuo Miura, Masami Hirano, Yasuo Morishima, Hiroshi Shiku, Ryuzo Ueda, Shigeo Nakamura
Journal: Blood (2007)
Use Of Unrelated Donors In Elderly Patients (age &gt;60 years) Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation For Hematologic Malignancies
Authors: El-Cheikh Jean, Devillier Raynier, Fürst Sabine, Crocchiolo Roberto, Granata Angela, Faucher Catherine, Mohty Bilal, Harbi Samia, Bouabdallah Reda, Vey Norbert, Castagna Luca, Chabannon Christian, Didier Blaise
Journal: Blood (2013)
Thrombocytopenia Is More Common and Nadir Occurs Earlier with Unfractionated Heparin Than with Low Molecular Weight Heparin - Results from the Prospective Catch Registry.
Authors: Stephan Moll, Charles S. Abrams, Lawrence Rice, Richard C. Becker, Peter B. Berger, Kevin J. Anstrom, Emily F. Honeycutt, Eric M. Crespo, Chris Granger, David J. Moliterno, Jo E. Rodgers, Steven R. Steinhubl, Victor F. Tapson, Magnus Ohman
Journal: Blood (2004)
P128 Pooled safety analysis of adjudicated serious adverse events with the combination of tiotropium + olodaterol: Abstract P128 Table 1
Authors: R Buhl, K Tetzlaff, L Korducki, C Vogelmeier, L McGarvey
Journal: Thorax (2015)

<h3>Rationale</h3> This analysis aimed to obtain a comprehensive and objective safety assessment of the combination of tiotropium (T), a long-acting muscarinic antagonist, with olodaterol (O), a long-acting β<sub>2</sub>-agonist, (T+O) in patients with moderate to very severe chronic obstructive pulmonary disease (COPD). <h3>Methods</h3> Data from two, 52-week, pivotal Phase III trials investigating T+O 5/5 µg and T+O 2.5/5 µg versus T 2.5 µg, 5 µg and O 5 µg were pooled, and patient narratives and profiles of serious adverse-event (SAE) reports were reviewed by an independent Adjudication Committee. The committee members independently assessed all SAEs to determine if any deaths, hospitalisations or intubations were respiratory-related, cardiovascular-related, cerebrovascular-related or other event-related. For an SAE adjudicated as respiratory-related, determination was made if it was related to COPD or pneumonia. For an SAE adjudicated as cerebrovascular-related, determination was made if it was related to stroke or other cerebrovascular events. Incidences of the composite end point (death, hospitalisation and intubation for respiratory-, cardiovascular-, cerebrovascular- or other-related events) and the individual components of this end point were evaluated. <h3>Results</h3> The safety population for the primary analysis included patients from two trials (NCT01431274 and NCT01431287) in which 799/5162 (15.5%; range across treatments: 14.3–16.5%) had any adjudicated event of interest. As expected in a moderate to very severe COPD population, most SAEs were respiratory-related (8.1%; 420 patients). Eighty-three (1.6%) patients had cardiovascular-related SAEs and 27 (0.5%) had cerebrovascular-related SAEs; 363 (7.0%) had SAEs that were adjudicated as non-respiratory-, non-cardiovascular- or non-cerebrovascular-related. Most adjudicated SAEs (763 patients; 14.8%) were hospitalisations, while there were 26 (0.5%) patients with intubation and 75 (1.5%) with fatal SAEs (86 [1.7%] had fatal SAEs when including vital status follow-up). <h3>Conclusions</h3> The adjudicated analysis of SAEs demonstrated that the risk of having an event (composite end point of hospitalisations, intubations and death whether related to respiratory, cardiovascular, cerebrovascular or other cause) was similar for T+O 5/5 μg compared to T+O 2.5/5 μg or any of the monotherapy components. Similar conclusions can be drawn for the individual events of hospitalisations, intubations and death.
Effectiveness of chemical pleurodesis in spontaneous pneumothorax recurrence prevention: a systematic review
Authors: R J Hallifax, A Yousuf, H E Jones, J P Corcoran, I Psallidas, N M Rahman
Journal: Thorax (2016)

<h3>Objectives</h3> Spontaneous pneumothorax is a common pathology. International guidelines suggest pleurodesis for non-resolving air leak or recurrence prevention at second occurrence. This study comprehensively reviews the existing literature regarding chemical pleurodesis efficacy. <h3>Design</h3> We systematically reviewed the literature to identify relevant randomised controlled trials (RCTs), case–control studies and case series. We described the findings of these studies and tabulated relative recurrence rates or ORs (in studies with control groups). Meta-analysis was not performed due to substantial clinical heterogeneity. <h3>Results</h3> Of 560 abstracts identified by our search strategy, 50 were included in our systematic review following screening. Recurrence rates in patients with chest tube drainage only were between 26.1% and 50.1%. Thoracoscopic talc poudrage (four studies (n=249)) provided recurrence rates of between 2.5% and 10.2% with the only RCT suggesting an OR of 0.10 compared with drainage alone. In comparison, talc administration during video-assisted thoracic surgery (VATS) from eight studies (n=2324) recurrence was between 0.0% and 3.2%, but the RCT did not demonstrate a significant difference compared with bleb/bullectomy alone. Minocycline appears similarly effective post-VATS (recurrence rates 0.0–2.9%). Prolonged air leak and recurrence prevention using tetracycline via chest drain (n=726) is likely to provide recurrence rates between 13.0% and 33.3% and autologous blood patch pleurodesis (n=270) between 15.6% and 18.2%. <h3>Conclusions</h3> Chemical pleurodesis postsurgical treatment or via thoracoscopy appears to be most effective. Evidence for definitive success rates of each agent is limited by the small number of randomised trials or other comparative studies.
P0416 : Relevance of BMP9-mediated signaling in oval cell function during liver injury. Crosstalk with the HGF/Met pathway
Authors: A. Addante, M. García-Álvaro, C. Roncero, L. Almalé, N. Deleyto, M. Fernández, I. Fabregat, B. Herrera, A. Sánchez
Journal: Journal of Hepatology (2015)
A Monoclonal Antibody Specific for Free Human Kappa Light Chains Induces Apoptosis of Multiple Myeloma Cells and Exhibits Anti-Tumor Activity In Vivo.
Authors: Parisa Asvadi, Darren R. Jones, Rosanne D. Dunn, Andre B.H. Choo, Matthew J. Raison, Robert L. Raison
Journal: Blood (2004)
Unusual Hematologic Malignancies
Authors: Jianguo Tao, Keith Flaherty, Adam Bagg
Journal: Journal of Clinical Oncology (2002)

Article Tools DIAGNOSIS IN ONCOLOGY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2002.20.17.3737 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 12202674 Unusual Hematologic Malignancies Case 1. Hematologic Malignancy Presenting With Diarrhea and Bony Lesions: Systemic Mastocytosis Jianguo TaoxJianguo TaoSearch for articles by this author , Keith FlahertyxKeith FlahertySearch for articles by this author , Adam BaggxAdam BaggSearch for articles by this author Show More University of Pennsylvania, Philadelphia, PA https://doi.org/10.1200/JCO.2002.20.17.3737 First Page Full Text PDF Figures and Tables © 2002 by American Society of Clinical Oncology
INTER-INDIVIDUAL RESPONSES OF MAXIMAL OXYGEN UPTAKE TO EXERCISE TRAINING: A CRITICAL REVIEW
Authors: P Williamson, G Atkinson, A Batterham
Journal: British Journal of Sports Medicine (2016)

We recently reported how to quantify the inter-individual differences in response to an intervention. We now aim to scrutinise the research on the individual responses to training of maximal oxygen uptake (VO 2 max). The key trigger for further investigation into individual responses is when the standard deviation of change (SD change ) in the intervention sample is substantially larger than the same standard deviation derived from a suitable comparator sample. ‘True’ inter-individual response can then be inferred. Six relevant studies from the influential HERITAGE family study were published in the 1980s. Unfortunately, only one of these studies included a comparator arm (1) Re-analysis of data from this study, accounting for random within-subjects variation, revealed an absence of clinically important individual difference in VO 2 max response. The SD change was, in fact, larger (±5.6 ml/kg/min) for the comparator than the intervention group (±3.7 ml/kg/min). Over 180 publications have now resulted from The HERITAGE study, but the crucial comparator arm is absent in all of these studies. Some authors rationalized this absence by claiming that only inter-individual differences in exercise response were of interest. This absence of a comparator sample is also the case in some present on-going studies. Again, re-analysis of data from the most recent studies does not suggest clinically relevant inter-individual differences in response. We also have concerns about the intraclass correlation coefficient approach to data analysis in twin studies. These are often heterogeneous for the obviously influential factors of sex, age and fitness, thereby inflating an unadjusted coefficient. We conclude that most studies on individual differences in VO 2 max response have no comparator sample. Therefore, ‘true’ individual response differences cannot be quantified. For those studies with a comparator sample, the difference between individual differences in response and random within-subjects variation is not clinically relevant.
UK government’s response to refugee children is “shameful,” say health leaders
Authors: Susan Mayor
Journal: BMJ (2016)

Leaders of UK medical colleges and nursing organisations have criticised the government’s response to the refugee crisis in a letter to a national newspaper, calling for a compassionate response to the plight of children after the clearance of the refugee camp in Calais, France.1

“Children are children, wherever in the world they happen to be. They deserve our protection and care, “said the letter, …
The Src family kinase inhibitor, dasatinib, inhibits angiogenesis in vitro and in vivo
Authors: Wei Liang, Andreas Herrmann, Michael Hedvat, Jianming Lu, Yun Yen, Wei Wen, Frank Lee, Richard Jove
Journal: Cancer Research (2008)

AACR Annual Meeting-- Apr 12-16, 2008; San Diego, CA

270 

Src family tyrosine kinases (SFKs) have essential roles in regulating multiple events involved in angiogenesis. We investigated the effects of dasatinib (BMS-354825), an orally bioavailable dual Src/Abl kinase inhibitor, on angiogenesis using both in vitro and in vivo models. Our results show that dasatinib inhibited VEGF- or bFGF-induced human endothelial cell (HUVEC) survival, migration and tube formation in vitro with IC50 values in the low nM range. Dasatinib-mediated HUVEC apoptosis was due to its ability to abrogate cell adhesion, consistent with a mechanism involving anoikis. These biological responses were associated with inhibition of the Src/FAK/p130CAS/paxillin signaling pathway following dasatinib treatment in the low nM range. Moreover, dasatinib was a potent inhibitor of ex vivo angiogenesis in a chick aortic ring assay. Using two-photon confocal microscopy, we examined the effect of dasatinib on tumor angiogenesis directly in vivo . Results show that dasatinib dramatically suppresses tumor angiogenesis in a human prostate cancer xenograft model. Taken together, these findings suggest that the anti-tumor activity of dasatinib may be at least partially due to its anti-angiogenic activity. This study also provides a rationale for clinical development of dasatinib as an anti-angiogenic therapeutic for cancer.
Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN
Authors: Laura Q.M. Chow, Chihiro Morishima, Keith D. Eaton, Christina S. Baik, Bernardo H. Goulart, Leslie N. Anderson, Kristi L. Manjarrez, Gregory N. Dietsch, James Kyle Bryan, Robert M. Hershberg, Mary L. Disis, Renato G. Martins
Journal: Clinical Cancer Research (2016)

Purpose: As Toll-like receptors (TLR) are key mediators of immune responses, TLR agonists may be important for augmenting the efficacy of therapies for squamous cell carcinoma of the head and neck (SCCHN). Motolimod (VTX-2337), a selective small-molecule agonist of TLR8, stimulates natural killer (NK) cells, dendritic cells, and monocytes. A phase Ib clinical trial assessed the safety and antitumor activity of motolimod in combination with cetuximab in patients with SCCHN. Correlative biomarkers of immune activity were explored.Experimental Design: Thirteen patients with recurrent or metastatic SCCHN were enrolled in this open-label, dose-escalation study using a standard 3 + 3 design. Doses of motolimod (2.5, 3.0, or 3.5 mg/m2) were given on days 1, 8, and 15, in combination with fixed weekly doses of cetuximab in 28-day cycles.Results: There were no protocol-defined dose-limiting toxicities, drug-related deaths, or evidence of synergistic toxicities between motolimod and cetuximab. Clinical tolerability at the 3.5 mg/m2 dose level was not optimal for repeated dosing and 3.0 mg/m2 was identified as the MTD. Two patients achieved partial responses for an overall response rate of 15%. Five patients had disease stabilization equating to a disease control rate of 54%. Statistically significant increases in plasma cytokines and in the frequency and activation of circulating NK cells were observed.Conclusions: Motolimod can be safely administered in combination with cetuximab with an acceptable toxicity profile. Encouraging antitumor activity and robust pharmacodynamic responses were observed. Motolimod is being further investigated in a phase II trial in patients with SCCHN (ClinicalTrials.gov ID: NCT01836029). Clin Cancer Res; 23(10); 2442-50. ©2016 AACR.
Characteristics and Clinical Course of Myeloma in Patients 40 Years of Age or Younger: A Study of the Greek Myeloma Study Group
Authors: Argiris Symeonidis, Efstathios Kastritis, Anastasia Sioni, Sosana Delimpasi, Eirini Katodritou, Eurydiki Michalis, Panagiotis Repousis, Zafiris Kartasis, Nora-Athina Viniou, Konstantinos Zervas, Evangelos Terpos, Meletios Athanasios Dimopoulos
Journal: Blood (2011)
Tetraspanin CD37 Directly Mediates Transduction of Survival and Apoptotic Signals
Authors: Rosa Lapalombella, Asha Ramanunni, Yuh-Ying Yeh, Liwen Wang, Shruti Jha, Justin Staubli, Sarah E. M. Herman, Leslie A Andritsos, Jeffrey A. Jones, Joseph M. Flynn, Xiaokui Mo, Amy J. Johnson, Peter Thompson, Paul A. Algate, Scott Stromatt, Michael A Freitas, Natarajan Muthusamy, John C. Byrd
Journal: Blood (2011)
Clinicopathological Prognostic Indicators Of 24 Patients With B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma
Authors: Ken-ichi Miyamoto, Akiko Miyagi Maeshima, Hirokazu Taniguchi, Junko Nomoto, Hideaki Kitahara, Suguru Fukuhara, Wataru Munakata, Dai Maruyama, Sung-Won Kim, Yukio Kobayashi, Kensei Tobinai
Journal: Blood (2013)
The Combination of 9-cis Retinoic Acid Plus MEK Inhibitor Induces Apoptosis Via Dephosphorylation of Retinoid X Receptor α in HL-60R Cells.
Authors: Nobuhiro Kanemura, Hisashi Tsurumi, Senji Kasahara, Takeshi Hara, Toshiki Yamada, Masahito Shimizu, Hisataka Moriwaki
Journal: Blood (2006)
Diagnostic Plasma-Derived Proteomic Biomarkers of Aggressive Diffuse Large B-Cell Lymphoma: Preliminary Data Based On the 075 French GEOLAMS Multicentric and Prospective Trial.
Authors: Delphine Maucort-Boulch, Marie Arlotto, Delphine Rossille, Céline Pangault, Pascal Roy, François Berger, Anita Burgun, Marie-Christine Béné, Thierry Lamy, Noel-Jean Milpied, Thierry Fest
Journal: Blood (2009)
Contribution of T-Cell Reconstitution during the Early Phase after Cord Blood Transplantation to Favorable Clinical Outcomes.
Authors: Satoshi Takahashi, Nobukazu Watanabe, Jun Ooi, Akira Tomonari, Kashiya Takasugi, Michihiro Uchiyama, Takaaki Konuma, Muneyoshi Futami, Yoshinori Yamanishi, Keisuke Takahashi, Arinobu Tojo, Tokiko Nagamura, Tsuneo A. Takahashi, Takehiko Mori, Shin-ichiro Okamoto, Hiromitsu Nakauchi, Shigetaka Asano
Journal: Blood (2004)